Advances in study on farnesoid X receptor in hepatocellular carcinoma

Abstract

Abstract: Farnesoid X receptor (FXR) is a ligand-activated transcription factor involved in the control of bile acid synthesis and enterohepatic circulation. In recent years, more and more studies have shown that the expression of hepatic FXR is inversely correlated with multiple malignant clinicopathological characteristics of hepatocellular carcinoma. This article reviewed the advances in study on FXR in hepatocellular carcinoma to provide necessary reference for the prevention and treatment of hepatocellular carcinoma.

Key words: Farnesoid X receptor, Bile acid, Liver cancer

Zhao Weihua, Li Changying. Advances in study on farnesoid X receptor in hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2025, 12(2): 22-25.

References

[1] HOOFNAGLE J H.FXR agonists as therapy for liver disease[J]. Hepatology, 2020, 72(1): 1-3.
[2] ZHOU J, CUI S, HE Q, et al.SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis[J]. Nat Commun, 2020, 11(1): 240.
[3] DAWSON P A.Hepatic bile acid uptake in humans and mice: multiple pathways and expanding potential role for gut-liver signaling[J]. Hepatology, 2017, 66(5): 1384-1386.
[4] CHIANG J Y L, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism[J]. Mol Cell Endocrinol, 2022, 548: 111618.
[5] FAN M, WANG X, XU G, et al.Bile acid signaling and liver regeneration[J]. Biochim Biophys Acta, 2015, 1849(2): 196-200.
[6] MASSAFRA V, VAN MIL S W C. Farnesoid X receptor: a "homeostat" for hepatic nutrient metabolism[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(1): 45-59.
[7] ZHENG R S, CHEN R, HAN B F, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 46(3) :221-231.
[8] SUN L, CAI J, GONZALEZ F J.The role of farnesoid X receptor in metabolic diseases,and gastrointestinal and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 335-347.
[9] LI T, APTE U.Bile acid metabolism and signaling in cholestasis,inflammation,and cancer[J]. Adv Pharmacol, 2015, 74: 263-302.
[10] KIMHOFER T, FYE H, TAYLOR-ROBINSON S, et al.Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review[J]. Br J Cancer, 2015, 112(7): 1141-1156.
[11] TAKAHASHI S, TANAKA N, FUKAMI T, et al.Role of farnesoid X receptor and bile acids in hepatic tumor development[J]. Hepatol Commun, 2018, 2(12): 1567-1582.
[12] ANAKK S, BHOSALE M, SCHMIDT V A, et al.Bile acids activate YAP to promote liver carcinogenesis[J]. Cell Rep, 2013, 5(4): 1060-1069.
[13] YOSHIMOTO S, LOO T M, ATARASHI K, et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature, 2013, 499(7456): 97-101.
[14] MA C, HAN MJ, HEINRICH B, et al.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360(6391): 1-23.
[15] DEGIROLAMO C, MODICA S, VACCA M, et al.Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation[J]. Hepatology, 2015, 61(1): 161-170.
[16] KAINUMA M, TAKADA I, MAKISHIMA M, et al.Farnesoid X receptor activation enhances transforming growth factor β-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells[J]. Int J Mol Sci, 2018, 19(7): 1898.
[17] STOFAN M, GUO G L.Bile acids and FXR:novel targets for liver diseases[J]. Front Med(Lausanne), 2020, 7: 544.
[18] FERRELL J M, PATHAK P, BOEHME S, et al.Deficiency of both farnesoid x receptor and takeda g protein-coupled receptor 5 exacerbated liver fibrosis in mice[J]. Hepatology, 2019, 70(3): 955-970.
[19] HUANG X F, ZHAO W Y, HUANG W D.FXR and liver carcinogenesis[J]. Acta Pharmacol Sin, 2015, 36(1): 37-43.
[20] LIU N, MENG Z, LOU G, et al.Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression[J]. Mol Endocrinol, 2012, 26(5): 775-785.
[21] MENG Z,WANG X, GAN Y, et al.Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice[J]. J Hepatol, 2012, 57(5): 1004-1012.
[22] ZHANG Y, GE X, HEEMSTRA L A, et al.Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in Ob/Ob mice[J]. Mol Endocrinol, 2012, 26(2): 272-280.
[23] CARIELLO M, PERES C, ZERLOTIN R, et al.Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4-/- mice[J]. Sci Rep, 2017, 7(1): 11203.
[24] KONG B, ZHU Y, LI G, et al.Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(5): 295-302.
[25] ZHANG C,WANG Z,FENG Q, et al.Farnesoid X receptor: a potential therapeutic target in multiple organs[J]. Histol Histopathol, 2020, 35(12): 1403-1414.
[26] TAKAHASHI S, TANAKA N, GOLLA S, et al.Editor's highlight:Farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury through the taurocholate-JNK pathway[J]. Toxicol Sci, 2017, 158(2): 334-346.
[27] KONG B, WANG L, CHIANG J Y, et al.Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice[J]. Hepatology, 2012, 56(3): 1034-1043.
[28] LI Q, ZHAO Q, ZHANG C Z, et al.The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice[J]. J Physiol Biochem, 2018, 74(2): 247-260.
[29] RAJA A, PARK I, HAQ F, et al.FGF19-FGFR4 signaling in hepatocellular carcinoma[J]. Cells, 2019, 8(6): 536.
[30] CHEN J, DU F, DANG Y, et al.Fibroblast growth factor 19-mediated up-regulation of SYR-related high-mobility group Box 18 promotes hepatocellular carcinoma metastasis by transactivating fibroblast growth factor receptor 4 and Fms-related tyrosine kinase 4[J]. Hepatology, 2020, 71(5): 1712-1731.
[31] ZHOU M, LUO J, CHEN M, et al.Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15[J]. J Hepatol, 2017, 66(6): 1182-1192.
[32] JIA J, ZHOU X, CHU Q.Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer[J]. Mol Cell Biochem, Epub 2024.
[33] LEE K W, LIM S, KIM K D.The function of N-Myc downstream-regulated gene 2 (NDRG2) as a negative regulator in tumor cell metastasis[J]. Int J Mol Sci, 2022, 23(16): 9365.
[34] HE J, ZHAO K, ZHENG L, et al.Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells[J]. Mol Cancer, 2015, 14: 163.
[35] KIM R D, SARKER D, MEYER T, et al.First-in-human phase I study of fisogatinib(BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma[J]. Cancer Discov, 2019, 9(12): 1696-1707.
[36] LIU T, YANG H, FAN W, et al.Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer[J]. Gastroenterology, 2018, 155(2): 557-571.
[37] CARIELLO M, PERES C, ZERLOTINET R, et al.Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4-/- mice[J]. Sci Rep, 2017, 7(1): 11203.
[38] GONG Y, LI K, QIN Y, et al.Norcholic acid promotes tumor progression and immune escape by regulating farnesoid X receptor in hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 1-12.
[39] FENG S, XIE X, CHEN C, et al.Alpha-linolenic acid inhibits hepatocellular carcinoma cell growth through farnesoid X receptor/β-catenin signaling pathway[J]. Nutr Metab (Lond), 2022,19(1): 57.
[40] SHI J J, JIA X L, LI M, et al.Guggulsterone induces apoptosis of human hepatocellular carcinoma cells through intrinsic mitochondrial pathway[J]. World J Gastroenterol, 2015, 21(47): 13277-13287.
[41] GIRISA S, PARAMA D, HARSHA C, et al.Potential of guggulsterone,a farnesoid X receptor antagonist,in the prevention and treatment of cancer[J]. Explor Target Antitumor Ther, 2020, 1(5): 313-342.